Breaking News on Contract Research, Manufacturing & Clinical Trials

Catalent to provide cell lines for at least three Hisun biosimilars in China

16-Apr-2014 - Catalent will provide Hisun Pharmaceuticals with cell lines to help it develop infliximab, adalimumab and alemtuzumab biosimilars for the Chinese market.

Shift to CMO strategic alliances key to UK plant turnaround, says Patheon

14-Apr-2014 - Strategic alliances and speciality manufacturing have transformed the fortunes of a Patheon UK facility, the company says.

Pacira selects Patheon to manufacture Exparel citing anticipated sales

10-Apr-2014 - Anticipated demand for the drug Exparel has led to a contract win for Patheon, though NDA holder Pacira says it will maintain control of all aspects of the manufacturing process.

Neuland opens new facility in India as part of deal with Japanese company

10-Apr-2014 - CMO Neuland Laboratories has opened a new manufacturing facility in Hyderabad, India as part of its collaboration with Tokyo-based API Corporation (APIC).

Foreign customers look to US FDA as stamp of quality

09-Apr-2014 - Passing US FDA site inspections is vital to attracting international clients, a European API supplier has said.

Molecular Profiles' investment makes HME (bio)available for clients

08-Apr-2014 - Molecular Profiles has invested in hot melt extrusion (HME) and nano milling capabilities citing client demand for improving the bioavailablity of drugs.

News in brief

CMO to put old Pfizer plant in Tennessee to use with Amerigen pact

07-Apr-2014 - UPM will produce two generic drugs for Amerigen Pharmaceuticals at a former Pfizer facility under a new 10 year supply contract.

Pernix leaves CMO business behind, sells off last manufacturing facility in Texas

03-Apr-2014 - Pernix Therapeutics will no longer be a CMO as it has signed a definitive agreement to divest its Houston, Texas-based manufacturing operations to Woodfield Pharmaceutical to cut costs.

Lupin: Mexican buy a bridgehead to generics and API growth

01-Apr-2014 - Lupin has bought Mexican eye drugmaker Grin in a deal that gives it a “bridgehead” to grow its API and generics business in the region.

Cobra's French mAb customers to get R&D tax credit

01-Apr-2014 - French mAb developers that hire Cobra Biologics stand to benefit from tax breaks after the French Ministry of Higher Education and Research (MESR) named the CMO as a preferred provider.

Quality and IP issues driving sponsors away from Indian CMOs, experts say

01-Apr-2014 - Quality and IP issues are driving firms back to the US and Europe for their contract manufacturing according to experts, but Kemwell says there are still opportunities for Indian CMOs.

Cytovance extends mAb manufacturing agreement with Precision Biologics

28-Mar-2014 - CMO Cytovance Biologics is extending its manufacturing agreement with Precision Biologics to advance clinical trials with its leading monoclonal antibody candidate, which is being developed as a therapeutic candidate for...

EMA to rejig variations procedures and industry contact staff in April

26-Mar-2014 - Pharmaceutical firms working in Europe may need to update their address books next month after more reorganisation at the EMA.

Dispatches from interphex

Consolidation prevalent in industry, says third largest CMO

26-Mar-2014 - Aenova says the acquisition of Haupt Pharma and Patheon’s merger with DSM are evidence of consolidation in the CMO industry, as it looks to further increase its global footprint.

Cevec's cell line bypasses problems that have held back RSV vaccine

25-Mar-2014 - An expression system developed by Cevec Pharmaceuticals has achieved 'very high' titres and bypassed problems that beset other platforms, moving the possibility of a commercial respiratory syncytial virus (RSV) one step...

News from Interphex 2014

Catalent commits to ADCs by upping its stake in Redwood

25-Mar-2014 - Catalent has increased its stake in Redwood Biosciences telling us it is committed to the development of antibody-drug conjugates (ADCs) and the SMARTag technology platform.

AMRI to acquire CDMO Cedarburg for $41M

25-Mar-2014 - AMRI will acquire Cedarburg Pharmaceuticals for $38.2m (€27.7) in cash, plus $2.8m of assumed liabilities, to expand its API and drug development offerings.


Patheon and DSM crossover limited, more growth targeted says DPx

20-Mar-2014 - Patheon and DSM’s Pharma Products merger is “highly complementary” with crossover limited to North American oral solid manufacturing growth, says DPx as it targets further growth opportunities.

UK energy cuts good for pharma, API and chem firms says industry group

20-Mar-2014 - Efforts to cut industrial energy bills in the UK's 2014 Budget have been welcomed by the Chemical Industries Association (CIA), a group whose members include drug and ingredient makers.

Drug firms replaced as Lonza's biggest buyers in 2013

20-Mar-2014 - Drugmakers were replaced by buyers of cosmetics, hygiene and material protection ingredients as Lonza’s biggest customers in 2013 according to a report released by the Swiss CMO today.

Kemwell adds freeze-drying tech at Bangalore biologics plant

19-Mar-2014 - Kemwell has added commercial-scale lyophilisation capacity at its plant in Bangalore, India citing growing demand from the sterile injectables sector.

IPO positions Recipharm as mid-tier CMO with plans to grow through takeovers

19-Mar-2014 - Recipharm has given investors a sneak peak at its finances ahead of its IPO next month that establishes the firm as a mid-tier CMO with plans to grow through acquisitions.


Managing excipient supply needs risk guidance, not ‘fear’ says expert

19-Mar-2014 - US pharmaceutical firms ‘fear change’ and need guidance on assessing safe excipient supply to become more like their European counterparts, says a senior IPEC expert.

Shire not switching fill finish supplier responsible for VPRIV recall

18-Mar-2014 - Shire has recalled one batch of its Gaucher’s disease drug VPRIV in the US after problems at its fill finish contractor resulted in particulate matter ending up in the vials....

Hospira edges closer to completion of Orchid API deal in India

18-Mar-2014 - The Board of Directors at Indian firm Orchid has approved the sale of its API business to Hospira, bringing the acquisition a step closer to completion.

Key Industry Events

Interphex 2014

New York, NY 10001 / Conference and exhibition

Read more

Access all events listing